Senseonics Eversense® CGM Launches Integration with Glooko


Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the integration of Eversense CGM data into the Glooko diabetes data management platform.

This integration allows Eversense CGM data to be synced into Glookos platform directly from the Senseonics cloud. Eversense users will be able to view historical glucose and related data both in Glookos Mobile and Web Apps while continuing to get real-time readings from their Eversense Mobile App. Healthcare professionals can now view their patients data in the Glooko Population Tracker in interactive reports alongside other data residing in Glooko.

Glooko has a large database of millions of users who are now able to see a clearer picture of their glucose profiles by integrating Eversense CGM data, said Tim Goodnow, President and CEO of Senseonics. With personalized medicine at the forefront of health care, data integration between Eversense CGM and Glooko helps provide customized data for users, as well as healthcare providers. We believe this information can empower our community to help manage their diabetes with new insights and actions and, ultimately, improve lives.

The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and that can be removed, recharged and re-adhered without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.

“We are excited to launch support for the breakthrough Eversense CGM on the Glooko platform, said Russ Johannesson, CEO of Glooko. Eversense is an innovative solution for making glucose data more accessible, and we feel users will get tremendous value out of seeing this data correlated with food, activity, and medication information they log in Glooko to help them make treatment decisions.”

Patients who are interested in getting started on Eversense can sign up at Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348).

About Eversense

The Eversense Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

About Glooko

Glookos universal diabetes software products provide insights to improve outcomes for people with diabetes (PWDs) and their care teams. The Glooko product suite contains the diasend and Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems sync data from 190+ of the worlds most popular diabetes devices, major fitness and activity trackers and supplies personalized, timely patient data such as glucose level, food, insulin, medications, blood pressure and weight data. Trusted by the worlds leaders in diabetes care, our solutions cover more than 2.2 million PWDs and are used in 9,000 clinic locations in 23 countries across 15 languages. Learn more by visiting

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about the completion and results of the integration of its Eversense and Glooko platforms, and the benefits, advantages and convenience such integration offers people with diabetes, and other statements containing the words believe, expect, intend, may, projects, will, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties in the development and regulatory approval processes, uncertainties inherent in the commercial launch and commercial expansion of the Eversense product, and such other factors as are set forth in the risk factors detailed in Senseonics Annual Report on Form 10-K for the year ended December 31, 2017, Senseonics Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, and Senseonics other filings with the SEC under the heading Risk Factors. In addition, the forward-looking statements included in this press release represent Senseonics views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics views as of any date subsequent to the date hereof.

Senseonics Investor Contact
Lynn Lewis or Philip Taylor
[email protected]

Senseonics Media Contact:
SignalWest Public Relations
Christensen, 831-566-0275
[email protected]